PCR London Valves 2025 - In this interview, Dr Jonathan Schwartz, leading structural interventional cardiologist at the Sanger Heart and Vascular Institute, Lake Forest University (Charlotte, NC, US) shares his insights into the evolving landscape of transcatheter tricuspid valve therapies.

Dr Schwartz examines the latest real-world and clinical trial evidence for the EVOQUE and TriClip systems, focusing on their safety, clinical effectiveness, and key considerations for selecting the right patients. He discusses current debates surrounding optimal residual tricuspid regurgitation, the symptomatic improvements seen in treated patients, and the importance of thorough right ventricular assessment to maximise procedural success.

He also provides practical guidance on choosing between repair and replacement strategies, explores how institutional experience shapes outcomes, and addresses the complex technical challenges inherent to these advanced interventions.

Interview Questions: 
What are the key recent advances in transcatheter tricuspid therapies?
How do current devices compare in safety and outcomes?
What does the evidence show about benefits beyond symptom relief, such as mortality or hospitalizations?
Which patient groups benefit most from these interventions?
What guides your choice between repair and replacement?
What practical advice do you have for clinicians adopting these technologies?

Recorded on-site at London Valves 2025, London.
 

Editors: Mirjam Boros

Videographer: Oliver Miles
Support: This is an independent interview produced by Radcliffe Cardiology.